Piramal Pharma Limited — Board Meeting, 28-07-2025: Outcome of Board Meeting

Piramal Pharma's board has approved its consolidated financial results for the quarter ending June 30, 2025. The company reported revenue of Rs 1,933.71 Cr, but faced a net loss of Rs 81.70 Cr for the quarter. A notable point is an exceptional gain of Rs 20.74 Cr received from a legal settlement. This income helped cushion the quarterly loss, giving investors a clearer picture of the operational performance.